.png){kind=icon}
.png){kind=icon}
Return
Discovery through clinical sequencing in oncology
.png){kind=icon}
OA
AI
DOI：10.1038/s43018-020-0100-0.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
The molecular characterization of tumors now informs clinical cancer care for many patients. This advent of molecular oncology has been driven by the expanding number of therapeutic biomarkers that can predict sensitivity to both approved agents and investigational agents. Beyond its role in driving clinical-trial enrollments and guiding therapy in individual patients, large-scale clinical genomics in oncology also represents a rapidly expanding research resource for translational scientific discovery. Here we review the progress, opportunities, and challenges of scientific and translational discovery from prospective clinical genomic screening programs now routinely conducted for patients with cancer. Molecular characterization of tumors informs clinical cancer care. Here, Taylor and colleagues review the progress, opportunities, and challenges of scientific and translational discovery that leverages prospective data from clinical genomic screening.
Keywords:
FOR-MOLECULAR-PATHOLOGY
CLONAL HEMATOPOIESIS
CHECKPOINT BLOCKADE
KINASE INHIBITION
CHROMOSOMAL INSTABILITY
MUTATIONAL LANDSCAPE
INCIDENTAL FINDINGS
PRECISION MEDICINE
GERMLINE VARIANTS
METASTATIC CANCER
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
28.5
Papers:
1.2K
Citations:
1.1W